<div id="readability-page-1"><div><ul> <li>If you are wondering whether Fortrea Holdings at US$15.64 is still offering value after a strong run, or if you are late to the story, this article focuses on what the current price might be implying.</li> <li>The stock has moved sharply, with returns of 48.1% over the last 7 days, 73.6% over the last 30 days and 177.8% over the last year, although year to date it sits at a 7.0% decline.</li> <li>Recent market attention has centered on Fortrea's position within the life sciences and pharmaceutical services space, as investors reassess the prospects of contract research and related outsourcing businesses. That backdrop helps explain why the stock has drawn interest from those watching sector peers and potential consolidation themes.</li> <li>On Simply Wall St's 6 point valuation framework, Fortrea scores 5 out of 6. The sections that follow break down what different valuation methods are indicating today, before finishing with a broader way to think about what the numbers are really saying about this stock.</li> </ul> <p>Fortrea Holdings delivered 177.8% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.</p> <h3>Approach 1: Fortrea Holdings Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in current terms.</p> <p>For Fortrea Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow is about $193.4 million. Analyst estimates and subsequent extrapolations point to projected free cash flow of $195.6 million in 2030, with interim years such as 2026 and 2028 also modeled in the tens to low hundreds of millions. Simply Wall St uses analyst inputs for the earlier years, then extrapolates beyond that period.</p> <p>These projected cash flows are discounted to arrive at an estimated intrinsic value of $33.89 per share. Compared with the current share price of $15.64, this implies the stock is 53.9% undervalued on this DCF view.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Fortrea Holdings is undervalued by 53.9%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTA3"/><figcaption>FTRE Discounted Cash Flow as at May 2026</figcaption></figure> <p>Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Fortrea Holdings.</p> <h3>Approach 2: Fortrea Holdings Price vs Sales</h3> <p>For companies where investors focus on revenue potential, the P/S ratio is a useful gauge because it compares what the market is paying for each dollar of sales. It is especially relevant when earnings are not the main driver of valuation.</p> <p>In general, higher growth expectations and lower perceived risk can support a higher “normal” P/S multiple. Slower expected growth or higher risk tend to line up with a lower multiple. So the question is what looks reasonable for Fortrea today.</p> <p>Fortrea trades on a P/S of 0.55x. That sits well below the Life Sciences industry average P/S of 3.45x and the peer group average of 10.84x. Simply Wall St also calculates a Fair Ratio for Fortrea of 1.82x, which is the P/S level suggested after adjusting for factors such as the company’s growth profile, profit margins, industry, market cap and risk characteristics.</p> <p>This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it tries to line up Fortrea’s own fundamentals with what investors typically pay for similar profiles. Comparing 0.55x to the Fair Ratio of 1.82x points to the stock trading below that calibrated level.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/ps-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTA3"/><figcaption>NasdaqGS:FTRE P/S Ratio as at May 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.</p> <h3>Upgrade Your Decision Making: Choose your Fortrea Holdings Narrative</h3> <p>Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Fortrea Holdings to the hard numbers by linking your view on its future revenue, earnings and margins to a financial forecast and a fair value. You can then compare that fair value with the current price to help you judge whether the stock looks expensive or cheap. Everything updates automatically as fresh news or earnings arrive. This is why one investor might back a more optimistic Fortrea view that lines up with a Fair Value around US$16.00, while another leans toward a more cautious Fair Value closer to US$5.00, yet both can see exactly how their assumptions differ inside the Community page used by millions of investors.</p> <p>For Fortrea Holdings, however, we will make it really easy for you with previews of two leading Fortrea Holdings Narratives:</p> <p><strong>🐂 Fortrea Holdings Bull Case</strong></p> <p>Fair value in this bullish narrative: US$16.00 per share.</p> <p>Implied discount to that fair value at the last close of US$15.64: about 2.3% undervalued.</p> <p>Revenue growth assumption in this scenario: about 1.9% a year.</p> <ul> <li>Focuses on cost realignment, automation and AI tools like Risk Radar as key levers for margin expansion and efficiency relative to peers.</li> <li>Highlights Fortrea's clinical pharmacology capabilities, aging demographics and higher R&amp;D intensity as supports for future clinical trial demand and potential new high margin work.</li> <li>Flags risks around client concentration, competitive pricing and execution on cost saving plans, which could affect revenue stability and profitability if they do not play out as expected.</li> </ul> <p><strong>🐻 Fortrea Holdings Bear Case</strong></p> <p>Fair value in this more cautious narrative: about US$14.44 per share.</p> <p>Implied premium to that fair value at the last close of US$15.64: about 8.3% overvalued.</p> <p>Revenue growth assumption in this scenario: about 1.1% a year.</p> <ul> <li>Emphasizes that while AI tools and cost measures support efficiency, analysts are using more muted assumptions for revenue and margin recovery.</li> <li>Points to customer concentration, competitive pricing and reliance on third parties as potential constraints on margin improvement and future earnings.</li> <li>Notes that goodwill impairment and mixed analyst targets feed into a more restrained fair value, with limited upside implied from the current share price on these inputs.</li> </ul> <p>If you want to see how your own view stacks up against these bullish and cautious setups, it helps to read the underlying narratives in full and stress test their assumptions against your expectations for Fortrea's revenue, margins and risk profile. To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Fortrea Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>Do you think there's more to the story for Fortrea Holdings? Head over to our Community to see what others are saying!</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/3941c5b6-174f-45a8-9a3a-6b578cdbd6eb/chart/quote-price/query-ZGF0ZT0yMDI2LTA1LTA3"/><figcaption>NasdaqGS:FTRE 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

FTRE

<p>Fortrea Holdings (FTRE) has seen a significant share price surge, with returns of 48.1% in the last week and 177.8% over the past year, despite a 7.0% year-to-date decline. Analysts suggest the stock is undervalued, with a Discounted Cash Flow analysis indicating an intrinsic value of $33.89 per share, implying a 53.9% undervaluation. Additionally, the Price-to-Sales ratio of 0.55x is well below industry averages, further supporting the undervaluation claim. Investors are encouraged to consider Fortrea's potential in the life sciences sector amidst ongoing market interest.</p>

Is It Too Late To Consider Fortrea Holdings (FTRE) After Its Recent Share Price Surge?